H. Eghbali

发表

The EORTC strategy in the treatment of Hodgkin's lymphoma

J. Raemaekers, H. Eghbali, P. Carde, 2005, European journal of haematology. Supplementum.

I. de Mascarel, I. Soubeyran, P. Richaud, 2000, Critical reviews in oncology/hematology.

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.

A. Hagenbeek, K. Maclennan, M. van Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular lymphomas--a review of treatment modalities.

M. Debled, F. Bonichon, P. Richaud, 2000, Critical reviews in oncology/hematology.

Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials

J. Raemaekers, E. Noordijk, H. Kluin-Nelemans, 2009, Haematologica.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

D. de Jong, E. Noordijk, A. Stamatoullas, 2017, International journal of radiation oncology, biology, physics.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

J. Raemaekers, A. Hagenbeek, G. Salles, 2007, The New England journal of medicine.

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

C. Sebban, M. Henry-Amar, E. Noordijk, 2005 .

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.

V. Diehl, J. Raemaekers, J. Radford, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.

N. Le Stang, J. Raemaekers, E. Noordijk, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

J. Raemaekers, A. Hagenbeek, J. Baars, 2003, The New England journal of medicine.

Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

I. Soubeyran, V. Coulon, E. Fabre-Guillevin, 2006, Leukemia & lymphoma.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Hodgkin’s Malignant Lymphomas

M. Durand, H. Eghbali, B. Hœrni, 1982 .

Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients.

J. Coindre, B. Hoerni, F. Bonichon, 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Hodgkin's disease in the elderly: A series of 30 patients aged older than 70 years

I. de Mascarel, M. Durand, B. Hoerni, 1984, Cancer.

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.

P. Vrignaud, J. Robert, A. Iliadis, 1985, European journal of cancer & clinical oncology.

Adjuvant bacillus Calmette-Guérin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution.

A. Ravaud, B. Hoerni, H. Eghbali, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

A. Ravaud, B. Bui, J. Mihura, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’

A. Hagenbeek, E. Noordijk, U. Tirelli, 1997 .

Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease

J. Rojouan, R. Zittoun, H. Eghbali, 1991, Journal of Cancer Research and Clinical Oncology.

Benign lymphocytic angiitis and granulomatosis: a T-cell lymphoma?

E. Labouyrie, F. Capron, J. Merlio, 1992, Human pathology.

Competitive polymerase chain reaction to quantify tumor cells in peripheral blood of patients with T(14;18)‐bearing follicular non‐Hodgkin's lymphoma: An exploratory study in 8 patients

I. Soubeyran, M. Debled, I. Hostein, 1999, International journal of cancer.

Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: results of a pilot study.

G. Marit, B. Hoerni, P. Richaud, 1998, International journal of radiation oncology, biology, physics.

Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients.

B. Hoerni, F. Bonichon, P. Richaud, 1991, European journal of cancer.

Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients. Pierre and Marie Curie Group (GPMC).

A. Audebert, B. Hoerni, J. Rojouan, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Tentative dose-monitoring of doxorubicin in lymphoma patients

P. Vrignaud, J. Robert, T. Nguyen-Ngoc, 1985, Medical oncology and tumor pharmacotherapy.

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

P. Feugier, S. Leprêtre, B. Grosbois, 2008, British journal of haematology.

Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884

A. Hagenbeek, C. Sebban, U. Tirelli, 2001 .

Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients.

J. Coindre, B. Hoerni, H. Eghbali, 1987, Oncology.

Normal levels of peripheral CD19+CD5+ CLL‐like cells: Toward a defined threshold for CLL follow‐up—A GEIL‐GOELAMS study

P. Feugier, F. Durrieu, M. Béné, 2011, Cytometry. Part B, Clinical cytometry.

Prognostic value of phenotyping by Ber-H2, Leu-M1, EMA in Hodgkin's disease.

J. Coindre, I. de Mascarel, F. Bonichon, 1990, Archives of pathology & laboratory medicine.

A 1-Kb Bcl-2-PCR Fragment Detection in a Patient With Follicular Lymphoma and Development of a New Diagnostic PCR Method

I. Soubeyran, M. Debled, I. Hostein, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Polymerase Chain Reaction Diagnosis of t(14;18) From Paraffin‐Embedded Tissues Fixed With Holland Bouin Fluid

I. Soubeyran, I. Hostein, M. Longy, 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

The impact of lymphoma and treatment on male fertility

H. Eghbali, A. Papaxanthos-Roche, 2010, Expert review of hematology.

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

J. Rossi, R. Gressin, E. Deconinck, 2010, British journal of haematology.

Maintenance immunotherapy with BCG in non-Hodgkin's malignant lymphomas: a progress report of randomized trial.

M. Durand, B. Hoerni, P. Richaud, 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.

S. Leprêtre, S. Chevret, F. Davi, 2011, Blood.

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas

I. Soubeyran, M. Debled, I. Hostein, 1999, British Journal of Cancer.

Distinct entities among low-grade non-Hodgkin's malignant lymphomas. Analysis of a series of 377 cases.

J. Coindre, B. Hoerni, O. Garraud, 1987, European journal of cancer & clinical oncology.

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

J. Raemaekers, A. Hagenbeek, E. Noordijk, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.

U. Tirelli, E. Noordijk, A. Mandard, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I-IIIA.

I. de Mascarel, B. Hoerni, F. Bonichon, 1988, European journal of cancer & clinical oncology.

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease.

J. Diebold, H. Merle-Beral, A. Audebert, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

J. Blay, B. Coiffier, R. Bouabdallah, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life during and after treatment of Hodgkin's disease.

B. Hoerni, H. Eghbali, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment

D. de Jong, D. Jong, M. Debois, 2011 .

Malignant Lymphoplasmacytoid Lymphomas. Clinical and Evolutive Data

M. Durand, B. Hoerni, H. Eghbali, 1978, Tumori.

Histiocytic sarcoma that mimicks benign histiocytosis

P. Dubus, M. Beylot-Barry, A. Mascarel, 1996 .

CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases.

P. Dubus, G. MacGrogan, J. Merlio, 1996, American journal of clinical pathology.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Augustin Ferrant, Chantal Doyen, J. Rossi, 2006 .

Gem‐(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non‐Hodgkin’s lymphoma – EORTC lymphoma group protocol 20021 (EudraCT number 2004‐004635‐54)

J. Raemaekers, I. Aurer, R. V. D. van der Maazen, 2011, European journal of haematology.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

M. Kersten, A. Hagenbeek, G. Salles, 2009, The Lancet. Oncology.

[Primary malignant non-Hodgkin's lymphoma of the breast. A study of 5 cases].

J. Coindre, I. de Mascarel, H. Eghbali, 1990, Annales de Pathologie.

Subsequent development of acute non‐lymphocytic leukemia in patients treated for Hodgkin's disease

A. Hagenbeek, W. van Putten, M. Durand, 1988, International journal of cancer.

Hodgkin's disease, clinical stages I and II. Results of radical irradiation with or without chemotherapy.

B. Hoerni, P. Richaud, H. Eghbali, 1980, Acta radiologica. Oncology.

Fludarabine phosphate-CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: a dose-finding study.

I. Soubeyran, B. Hoerni, H. Eghbali, 2005, European journal of cancer.

Kc,y wmk Follicular lymphomn. stages I and II; Radiothcritpy; Prognostic factors

J. Coindre, F. Bonichon, P. Richaud, 1988 .

[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].

B. Hoerni, H. Eghbali, P. Soubeyran, 1994, Bulletin du Cancer.

Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center.

B. Hoerni, F. Bonichon, P. Richaud, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.

V. Diehl, M. Sieber, M. Henry-Amar, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Distinctive clinical features between lymphoblastic and immunoblastic non‐Hodgkin's malignant lymphomas (Kiel's classification) in a series of 141 patients

J. Coindre, M. Durand, P. Richaud, 2007, Hematological oncology.

Non‐Hodgkin's malignant lymphomas in patients older than 80 70 Cases

B. Pégourié, H. Eghbali, J. Sotto, 1988, Cancer.

Semen analysis and cryoconservation before treatment in Hodgkin's disease.

J. Berjón, B. Hoerni, H. Eghbali, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

J. Raemaekers, G. Salles, D. de Jong, 2017, European journal of cancer.

Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.

B. Hoerni, H. Eghbali, G. Hoerni-simon, 1978, Acta radiologica: oncology, radiation, physics, biology.

Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.

J. Raemaekers, B. Coiffier, A. Allgeier, 2014, Human reproduction.

First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL)

E. Noordijk, M. Henry-Amar, F. Morschhauser, 2005 .

Histiocytic sarcoma that mimics benign histiocytosis.

P. Dubus, M. Beylot-Barry, H. Eghbali, 1996, Journal of cutaneous pathology.

The Caregivers Quality of Life Cancer index scale (CQoLC): an exploratory factor analysis for validation in French cancer patients’ spouses

N. Houédé, F. Cousson-Gélie, H. Eghbali, 2013, Quality of Life Research.

Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).

J. Raemaekers, E. Noordijk, Y. Lievens, 2005, International journal of radiation oncology, biology, physics.

[The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease. Phase II trials].

A. Audebert, B. Hoerni, J. Rojouan, 1987, Bulletin du cancer.

[Quality of life during and following radiochemotherapy for Hodgkin's disease. Evaluation of 60 patients].

B. Hoerni, P. Richaud, H. Eghbali, 1983, Bulletin du Cancer.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

J. Armitage, V. Diehl, T. Lister, 1998, The New England journal of medicine.

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas

I. Soubeyran, M. Debled, I. Hostein, 1999, British Journal of Cancer.

Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients.

V. Picot, B. Hoerni, F. Bonichon, 2002, Critical reviews in oncology/hematology.

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

I. de Mascarel, B. Hoerni, F. Bonichon, 1989, British Journal of Cancer.

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.

R. Rizzoli, C. Manegold, B. Thürlimann, 1999, The Journal of clinical endocrinology and metabolism.

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

J. Rossi, R. Gressin, E. Deconinck, 2010, British journal of haematology.

[Non-Hodgkin's malignant lymphomas. Clinico-pathological data and course in 370 patients (author's transl)].

M. Durand, B. Hoerni, P. Richaud, 1980, Bulletin du cancer.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

B. Pégourié, B. Grosbois, J. Mary, 2006, Blood.